Welcome to our dedicated page for Nanovibronix news (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on Nanovibronix stock.
NanoVibronix Inc. (NAOV) specializes in pioneering ultrasound-based medical devices for noninvasive pain management and infection prevention. This page aggregates official company announcements and verified news about therapeutic innovations, financial performance, and strategic partnerships.
Investors and healthcare professionals will find timely updates on FDA clearances, clinical trial results, and market expansions. Our curated collection includes earnings reports, product launch details, and research breakthroughs—all essential for tracking NAOV's position in the medical technology sector.
Key content categories include regulatory milestones for devices like UroShield®, financial disclosures, and partnership announcements with healthcare distributors. Bookmark this page to monitor how NAOV's low-intensity ultrasound technology addresses critical needs in wound care and catheter-associated infections.
NanoVibronix (NASDAQ: NAOV) announced a distribution agreement with CB Medical, a VA-certified and Service-Disabled Veteran-Owned Small Business, for the sale and distribution of UroShield. UroShield, an ultrasound-based device, helps prevent bacterial colonization on urinary catheters, reduces catheter-associated urinary tract infections (CAUTI), and alleviates pain and discomfort. The multi-year agreement allows CB Medical to sell UroShield throughout the VA system in the U.S. Brian Murphy, CEO of NanoVibronix, highlighted the opportunity to expand UroShield's distribution and benefit veterans. Shawn Pinkston, CEO of CB Medical, emphasized the importance of offering effective solutions to veterans, especially those with spinal injuries who use indwelling catheters and are at high risk of infection.
NanoVibronix, Inc. announced that its PainShield product will be included in the U.S. Department of Veteran Affairs’ Federal Supply Schedule (FSS) effective May 1, 2024. The five-year contract awarded to distribution partner Delta Medical, will provide a significant opportunity for NanoVibronix to expand the placement of PainShield devices within the VA healthcare network, serving nine million enrolled veterans annually. The contract aims to address the growing need for non-pharmacological pain management solutions, positioning PainShield as a valuable therapeutic option.
FAQ
What is the current stock price of Nanovibronix (NAOV)?
What is the market cap of Nanovibronix (NAOV)?
